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Effect of Liver Dysfunction on Cyclosporine 
Pharmacokinetics 
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R.J. Ptachcinski, and R. Venkataramanan 
THERAPY WITH CYCLOSPORINE (CsA) constitutes a major advance lead-
ing to the success of organ transplantation. 1- 3 
CsA is a lipophilic drug and is poorly and 
variably absorbed in transplant patients.4 It is 
primarily eliminated from the body by hepatic 
metabolism.s Alterations in the hepatic func-
tion would therefore be expected to change the 
kinetics of CsA. We determined the effect of 
experimentally induced hepatic dysfunction 
on the pharmacokinetics of CsA in dogs. 
METHODS 
Kinetic studies were carried. out in adult mongrel dogs 
prior to and during week 1 after 70% hepatectomy 
(n - 6) or 2 weeks after bile duct ligation (BDL) (n - 6). 
esA was administered as an intravenous infusion (2 
mg/kg) for 1.0 to 1.5 hours or given orally (17.5 mg/kg) 
on separate occasions with at least a three-day washout 
time period between treatment. Blood samples (3 mL) 
were obtained from the jugular vein just prior to and at 
0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours after 
intravenous administration and at 1,2,3,4,6,8, 12, 16, 
and 24 hours after oral administration. Blood esA con-
centrations were determined by high-performance liquid 
chromatography.6 Pharmacokinetic parameters were cal-
culated according to standard procedures. 
Liver function was assessed in all the dogs by deter-
mining indocyanine green (leG) kinetics at two doses 
(0.5 and 5.0 mg/kg) prior to and following surgically 
induced liver disease. The leG plasma disappearance 
rate constant (K) and the maximal removal rate (V mu) 
were evaluated. Serum bilirubin levels were also mea-
sured in all the animals. 
RESULTS 
Serum bilirubin levels were significantly 
increased in all the animals after BDL or 
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hepatectomy. Following hepatectomy, leG K 
and V max were reduced by 61.3% (± 9.7%) 
(P < .001) and 57.7% (±7.1%) (P < .001), 
respectively as compared with control values. 
There was a significant decrease in the CsA 
half-life after hepatectomy. The mean (±SD) 
CsA clearance of 3.85 (±0.61) mL/min/kg 
after hepatectomy was significantly lower 
than the mean (±SD) clearance of 7.09 
(±2.l) mL/min/kg prior to the hepatic dys-
function. However, there was no difference in 
the volume of distribution of CsA after hepa-
tectomy. The absolute oral bioavailability of 
CsA was decreased by 26.4% ± 14.8% (P < 
.05) after hepatectomy. 
BDL also induced a significant hepatic 
dysfunction. ICG K and V max were reduced by 
65.6% ± 3.6% and 39.1% ± 12.8%, respec-
tively. The mean (±SD) clearance of CsA 
decreased (P < .05) from 7.09 ± 2.1 to 5.37 ± 
0.92 mL/min/kg. There was no difference in 
the volume of distribution of CsA after BDL. 
There was a marked reduction in the mean 
(±SD) absolute oral bioavailability from 
21.8% ± 4.4% to 5.7% ± 3.4%. 
DISCUSSION 
CsA is extensively metabolized in the liver 
by the cytochrome P-450 system.s Less than 
1 % of the drug is excreted as unchanged CsA 
in the bile. However, the metabolites of CsA 
are primarily excreted through the bile. 
Therefore hepatic dysfunction was expected 
to alter its kinetics. 
Hepatic dysfunction was confirmed in all 
the animals after BDL or hepatectomy by 
elevated serum bilirubin levels and by impair-
ment in rCG kinetics. Even though both the 
models produced significant alterations in 
CsA kinetics, the extent of impairment in 
kinetic parameters was different in the two 
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models studied. ICG V max. which is a highly 
sensitive index of hepatic cell function, is 
reduced to a greater extent after hepatectomy 
than after BDL. BDL resulted in a lesser 
impairment in the ICG V max and the clearance 
of CsA as compared with hepatectomy. 
Changes in ICG V max and CsA clearance 
appeared to parallel each other in all the 
animals. BDL markedly impaired the bio-
availability of CsA as compared with hepatec-
tomy. This may be due to the lack of availabil-
ity of bile for the absorption of CsA in BDL 
animals. Though the bile flow may have been 
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diminished to a certain extent in the hepatec-
tomized animals, some bile was apparently 
available for CsA absorption. Previous studies 
in animals and humans indicate that bile is 
essential for CsA absorption.7•8 
The present study indicates that hepatic 
dysfunction not only alters the elimination of 
CsA but also impairs its absorption. Since the 
impairment in CsA kinetics appears to vary 
with the degree and the cause of hepatic 
dysfunction, individualization of the CsA dos-
ing regimen is necessary in patients with hepa-
tic insufficiency. 
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